Altimmune, Inc. Form 8-K Summary
Business Context and Reporting Period
Altimmune, Inc. (NASDAQ: ALT) filed a Current Report on Form 8-K dated January 27, 2026. The filing announces the entry into a Material Definitive Agreement for a registered direct offering of equity securities.
Key Financial Metrics and Transaction Details
The Company entered into a Securities Purchase Agreement to issue the following securities to a new fundamental institutional investor:
- Common Stock: 12,397,920 shares.
- Pre-Funded Warrants: Warrants to purchase up to 4,647,534 shares of Common Stock.
- Gross Proceeds: Approximately $75 million (before placement agent fees and offering expenses).
- Placement Agent: Titan Partners Group LLC (a division of American Capital Partners, LLC).
- Expected Closing Date: On or about January 29, 2026.
The filing does not provide specific values for revenue, profit, cash flow, margins, or existing debt levels, as this report focuses solely on the capital raise transaction.
Material Changes and Transaction Terms
This transaction represents a significant capital raise intended to bolster the Company's liquidity. Key terms include:
- Warrant Terms: Pre-Funded Warrants are exercisable at any time after issuance for one share of common stock each. The purchase price equals the offering price less a $0.001 exercise price. They do not expire.
- Ownership Limitations: A "Beneficial Ownership Limitation" of 9.99% applies, adjustable up to 19.99% with written notice (effective 61 days after notice).
- Lock-Up Agreements: The Company, its directors, and executive officers are subject to a 30-day lock-up period following the closing of the Offering.
- Expenses: The Company agreed to pay a cash fee to the placement agent based on gross proceeds and reimburse expenses up to $125,000.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on operational outlook, or specific risk factors beyond standard legal disclaimers. The transaction is subject to customary closing conditions. The Pre-Funded Warrants will not be listed on the Nasdaq Global Market or other national securities exchanges.
Investor Verification Checklist
- Verify the final closing date and actual gross proceeds received after fees.
- Confirm the exact purchase price per share and per warrant to calculate the total dilution impact.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and indemnification obligations.
- Monitor the Company's cash position post-closing to assess runway extension.
- Check for any subsequent filings regarding the exercise of Pre-Funded Warrants or changes to the Beneficial Ownership Limitation.